What changed
$JNJ — Develops and sells healthcare products and pharmaceuticals.
🎯 Q1 FY26 | Rev $24B | EPS $2.70 vs $2.68 🟢
💡 Consensus expects steady growth from JNJ's diversified healthcare portfolio, but the market may be underestimating the impact of rising R&D spend (14.7% of revenue) and a sharp decline in operating cash flow ($2.5B vs $4.2B YoY) on near-term earnings quality.
🏢 Business Quality: 8/10 | Valuation: fair
📉 Reward/Risk: Upside 8% to $260 (target based on 17x FY26 EPS) vs downside 12% to $210 (15x FY26 EPS on cash flow miss). Ratio: 0.67x, unfavorable.
🔮 Catalyst: Q2 2026 earnings (late July): watch for revenue growth sustaining >5% and operating cash flow recovery above $3.5B. Failure signal: further cash flow deterioration or guidance cut.
💰 Entry: Current price $240.54 is not attractive; ideal entry below $225 (16x FY26 EPS of ~$11.57) to build in margin of safety.
Also in play: $PFE $MRK $ABBV $NVS $LLY $DHR